Information:
Fel:
ID
17310
Beskrivning
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00619697
Länk
https://clinicaltrials.gov/show/NCT00619697
Nyckelord
Versioner (1)
- 2016-09-06 2016-09-06 -
Uppladdad den
6 september 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes NCT00619697
Eligibility Diabetes NCT00619697
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT00619697
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Non-Insulin-Dependent Diabetes Mellitus disease length
Item
type 2 diabetes for at least 6 months
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0872146 (UMLS CUI [1,2])
Insulin Therapy naive | Insulin, Short-Acting
Item
insulin naive. short term insulin treatment (7 days or less within the last 6 months) is allowed
boolean
C0021641 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0356365 (UMLS CUI [2])
C0919936 (UMLS CUI [1,2])
C0356365 (UMLS CUI [2])
Oral hypoglycemic
Item
previous treatment with oral antidiabetic drugs for at least 4 months
boolean
C0359086 (UMLS CUI [1])
Indication Insulin regime | Insulin Analogue | Oral hypoglycemic
Item
judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen
boolean
C3146298 (UMLS CUI [1,1])
C0557978 (UMLS CUI [1,2])
C2825028 (UMLS CUI [2])
C0359086 (UMLS CUI [3])
C0557978 (UMLS CUI [1,2])
C2825028 (UMLS CUI [2])
C0359086 (UMLS CUI [3])
Body mass index
Item
bmi below 40 kg/m2
boolean
C1305855 (UMLS CUI [1])
Glycosylated hemoglobin A
Item
hba1c between 7-12%
boolean
C0019018 (UMLS CUI [1])
Plasma Glucose Measurement Self Monitoring Willing
Item
able and willing to perform self-plasma glucose monitoring
boolean
C0202042 (UMLS CUI [1,1])
C0588436 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
C0588436 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Investigational New Drugs
Item
the receipt of any other investigational drug within 4 weeks before screening
boolean
C0013230 (UMLS CUI [1])
Substance Use Disorders
Item
a history of drug or alcohol abuse within the last 12 months
boolean
C0038586 (UMLS CUI [1])
Uncontrolled hypertension Severe
Item
severe, uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Related Investigational New Drugs
Item
known or suspected allergy to trial products or related products
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0013230 (UMLS CUI [2,4])